JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony zaawansowany lub nieoperacyjny rak płuca bez małych komórek z mutacją KRAS G12C
- •Brak wcześniejszego leczenia systemowego na zaawansowane stadium
- •Spodziewana przeżywalność co najmniej 3 miesiące
- •Co najmniej jedno zmierzone ognisko nowotworu
- •Dobry ogólny stan zdrowia (ECOG ≤ 1)
- •Podpisana świadoma zgoda na uczestnictwo w badaniu
✗ Disqualifies
- •Inne nowotwory (w ciągu ostatnich 2 lat lub aktualnie)
- •Inne mutacje genowe wrażliwe na dostępne leczenie celowane
- •Przerzuty do mózgu bez leczenia
- •Niekontrolowana kumulacja płynu wokół płuc, serca lub w brzuchu
- •Poważne problemy z pracą serca lub choroba serca
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (37)
Anhui Province cancer hospital
Hefei, China
Pecking Union Medical College Hospital
Beijing, China
Cancer Hospital Chinese Academy Of Medical Sciences
Beijing, China
Beijing Tiantan Hospital, Captal Medical University
Beijing, China
Beijing Cancer Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Beijing Chest Hospital ,Capital Medical University
Beijing, China
Fujian cancer Hospital
Fuzhou, China
The first Affiliated Hospital, Sun Yat-sen University
Guangzhou, China
Cancer Hospital Chinese Academy Of medical Sciences Shenzhen Center
Shenzhen, China
Guangxi Medical University Cancer hospital & Guangxi Cancer Institute
Nanning, China
Cangzhou hospital of integrated TCM-WM Hebei
Cangzhou, China
Harbin Medical University Cancer Hospital-Mammary gland of internal
Haerbin, China
Henan Cancer Hospital
Zhengzhou, China
The First Affiliated Hosipital Of Zhengzhou University
Zhengzhou, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
Tongji Hospital Tongji Medical College of Hust
Wuhan, China
Hubei cancer hospital
Wuhan, China
Hunan Cancer Hospital
Changsha, China
Jiangsu province hospital
Nanjing, China
Wuxi People's Hospital
Wuxi, China
Jilin cancer hospital
Jilin City, China
The First Hospital Of China Medical University
Shenyang, China
Liaoning Cancer Hospital & Institute
Shenyang, China
Shandong Cancer Hospital
Jinan, China
LinYi Cancer Hospital
Linyi, China
The affiliated hospital of Qingdao university
Qingdao, China
Fudan University Shanghai Cancer Center
Shanghai, China
Shanghai Pulmonary Hospital
Shanghai, China
Shanxi province cancer hospital
Taiyuan, China
The First Affiliated Hospital of Xi'An Jiaotong University
Xi’an, China
Sichuan province cancer hospital
Chengdu, China
West China Hospital Sichuan University
Chengdu, China
Tianjin Medical University Cancer Institute Hospital
Tianjin, China
The First affiliated hospital Zhejiang university school of medicine
Hangzhou, China
The Second Affiliated Hospital Zhejiang School of Medicine
Hangzhou, China
Taizhou Hospital Zhejiang Province
Taizhou, China
Trial contact
Shanghai Allist Pharmaceuticals Co., Ltd
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.